Inclusion Criteria:  - Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as first line of chemotherapy.  Exclusion Criteria:  Patients with histological diagnosis of metastatic LMS and SFT, received before 2010. Patients with histological diagnosis of metastatic LMS and SFT from 2010 to 2020, never treated with dacarbazine Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as the first line of chemotherapy, of which, however, there is no tissue sample